New Blood Test May Improve Ovarian Cancer Diagnosis, Study Suggests

New Blood Test May Improve Ovarian Cancer Diagnosis, Study Suggests
A blood test that examines a panel of 11 specific proteins could help distinguish between benign tumors and malignant ovarian cancer, reducing the need for unnecessary surgeries and leading to an earlier diagnosis, a study shows. Conducted by researchers at Uppsala University and Sahlgrenska Academy at the University of Gothenburg in Sweden, the study, “High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer,” was published in the journal Communications Biology. Ovarian cancer is one of the leading causes of cancer-related death in women around the world, mostly because the disease has no specific signs and symptoms and is often caught late, when the chances of curing it are low. When a woman is suspected of having ovarian cancer after an ultrasound, the only way to determine if it's a benign or malignant tumor is through surgery. This means that women who do not have cancer will undergo a surgical procedure they do not need, putting them at risk of side effects that could otherwise be avoided. "We need to develop more accurate pre-surgery diagnostics. To detect one cancer, we operate on up to five women — yet this is currently the best option when abnormalities are detected by ultrasound and cancer is suspected," Karin Sundfeldt, a professor and senior consultant in the department of obstetrics and gynecology at Sahlgrenska's Institute of Clinical Sciences, said in a
Subscribe or to access all post and page content.